Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01935960 · ClinicalTrials.gov registry record · Phase 1
Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT01935960 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants.
The verdict
NCT01935960, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
This randomized phase I trial studies the side effects and best dose of retinoid 9cUAB30 in preventing cancer in healthy volunteers. The use of retinoid 9cUAB30 may keep cancer from forming in healthy volunteers.
Interventions
- OTHER Placebo
- OTHER Laboratory Biomarker Analysis
- OTHER Pharmacological Study
- DRUG Retinoid 9cUAB30
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2013-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01935960
The ClinicalTrials.gov registry entry for NCT01935960 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01935960 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01935960 about?
NCT01935960 is a clinical study titled "Retinoid 9cUAB30 in Preventing Cancer in Healthy Volunteers". This randomized phase I trial studies the side effects and best dose of retinoid 9cUAB30 in preventing cancer in healthy volunteers. The use of retinoid 9cUAB30 may keep cancer from forming in healthy volunteers.
What is the current status of trial NCT01935960?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2013-08.
What interventions are being tested in trial NCT01935960?
The interventions under investigation include: Placebo (OTHER), Laboratory Biomarker Analysis (OTHER), Pharmacological Study (OTHER), Retinoid 9cUAB30 (DRUG).
Who is sponsoring clinical trial NCT01935960?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.